Valuation: Rapport Therapeutics, Inc.

Market Cap 1.48B 1.32B 1.23B 1.12B 2.11B 143B 2.13B 14.81B 5.79B 72.87B 5.56B 5.44B 234B P/E 2026 *
-7.37x
P/E 2027 * -6.2x
Enterprise Value 1.15B 1.03B 959M 871M 1.64B 112B 1.66B 11.52B 4.5B 56.67B 4.32B 4.23B 182B EV / Sales 2026 *
57.6x
EV / Sales 2027 * -
Free-Float
96.1%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rapport Therapeutics, Inc.

1 day-3.27%
1 week-11.16%
Current month-11.16%
1 month-34.78%
3 months-24.85%
6 months-10.87%
Current year-1.62%
1 week 29.45
Extreme 29.45
34.48
1 month 29.45
Extreme 29.45
45.42
Current year 25.21
Extreme 25.21
52.93
1 year 23.75
Extreme 23.75
52.93
3 years 6.43
Extreme 6.43
52.93
5 years 6.43
Extreme 6.43
52.93
10 years 6.43
Extreme 6.43
52.93
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 61 31/12/2022
Chief Executive Officer 48 31/01/2023
Director of Finance/CFO 58 31/10/2023
Director TitleAgeSince
Director/Board Member 61 22/08/2023
Director/Board Member 48 28/02/2023
Director/Board Member 54 31/01/2022
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Sell

Chief Operating Officer

-10,000 0.0208%
23/09/26 Sell

Chief Executive Officer

-2,210 0.0046%
08/09/26 Sell

Chief Executive Officer

-8,210 0.0171%
Change 5-day change 1-year change 3-year change Capi.($)
-3.27%-11.16%+12.90% - 1.48B
-3.19%-3.19%+44.60%+87.98% 74.68B
-15.86%-16.67%+3.92%+50.90% 58.7B
-2.39%-2.05%+4.29%+31.33% 48.36B
-6.35%-8.35%+303.95%+651.28% 43.05B
+0.30%-3.71%+28.89%+30.33% 42.48B
-3.82%-4.32%+2.49%+101.36% 41.39B
-2.13%+1.07%+7.51%+50.31% 31.29B
-3.35%-6.35%-13.20%-17.22% 23.93B
-1.24%-11.97%-38.10%+311.13% 22.22B
Average -4.11%-3.18%+35.73%+144.16% 38.76B
Weighted average by Cap. -4.84%-1.90%+44.58%+136.42%

Financials

2026 *2027 *
Net sales 20M 17.86M 16.66M 15.14M 28.48M 1.94B 28.76M 200M 78.24M 984M 75.09M 73.46M 3.17B -
Net income -195M -174M -162M -147M -277M -18.85B -280M -1.95B -762M -9.58B -731M -715M -30.81B -250M -223M -208M -189M -356M -24.18B -359M -2.5B -977M -12.29B -937M -917M -39.52B
Net Debt -329M -294M -274M -249M -469M -31.87B -473M -3.29B -1.29B -16.2B -1.24B -1.21B -52.09B -309M -276M -258M -234M -441M -29.96B -445M -3.09B -1.21B -15.22B -1.16B -1.14B -48.96B
Projected Income Statement - Annual - Rapport Therapeutics, Inc.
Logo Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders.
Employees
84
Date Price Change Volume
08/10/26 US$29.85 -3.27% 236,778
07/10/26 US$30.86 -0.93% 314,989
06/10/26 US$31.15 -3.23% 235,744
05/10/26 US$32.19 +0.06% 198,868
02/10/26 US$32.17 -2.01% 277,626
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Ratings Surperformance© - Rapport Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
30.86USD
Average target price
63.04USD
Spread / Average Target
+104.29%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Rapport Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. RAPP Stock